HealthTech January 26, 2026
The companies will invest up to $1 billion over five years to support discovery and development powered by artificial intelligence.
NVIDIA and Lilly are teaming up to address challenges in drug discovery. The two companies announced that they plan to invest up to $1 billion in an artificial intelligence (AI) co-innovation lab over five years.
The lab, which will be located in San Francisco, will use a “scientist in the loop” framework and will provide “ a continuous learning system that tightly connects Lilly’s agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists,” according to a press release.
In addition to large amounts of compute power, the lab will use NVIDIA’s BioNeMo platform...
Today's Sponsors
Today's Sponsor